CJC-1295 (No DAC), Ipamorelin, GHRP-2 (Blend)

pamorelin is one of the most selective growth hormone (GH) secretagogues known and a potent agonist of the ghrelin/growth hormone secretagogue receptor^[1]. It has been heavily researched in a number of settings and is known to, improve bone health, boost muscle repair and development, stimulate insulin release from the pancreas, and improve bowel motility and gastric function^[2]–[6].

CJC-1295 also causes the release of GH, but it does so by stimulating the growth hormone releasing hormone receptor. It is also highly selective and has demonstrated positive benefits on bone health, lean body mass, insulin resistance, and muscle growth and development^[7]–[9]. By combing the two peptides, it may be possible to produce enhanced effects because they stimulate the growth hormone axis via two different mechanisms. Research in animal models using both peptides is likely to show increased benefit without substantially increased side effects.

Ipamorelin is likely to raise baseline levels of GH such that CJC-1295 will be able to produce both higher peaks and higher troughs while preserving normal growth hormone pulsatile secretion. The net effect of combing the peptides would be a higher set point for the normal ebb and flow of GH, resulting in improved lean body mass, better muscle development, improved use of insulin, and overall better metabolic function.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.